Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Following residency in pediatrics and fellowship pediatric cardiology and a faculty position at Johns Hopkins, Dr Zahka moved to Cleveland as Director of Pediatric Cardiology at Rainbow Babies and Children's Hospital. After nearly 20 years at Rainbow he joined the staff of the Cleveland Clinic Children's Hospital in July 2009. He holds the academic rank of Professor of Pediatrics at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University School of Medicine.
His clinical focus is genetic forms of cardiovascular disease including hypertrophic cardiomyopathy and connective tissue diseases. His current clinical research centers on the understanding of the impact of the founder gene mutation of myosin binding protein C3 in the Old Order Amish. His current education focus is curriculum development to facilitate cardiology fellowship training in cardiopulmonary exercise testing and physiology.
He has been dedicated to the enhancement and development of cardiovascular care abroad, working with cardiologists in the Middle East, Kenya, Armenia, Russia and Ecuador. He has been recognized by Best Doctors in Cleveland from Cleveland Magazine and Best Doctors in America. He is a consultant for the Food and Drug Administration and the genetic testing company, Familion.
Genetic cardiovascular disease: hypertrophic cardiomyopathy, Marfan Syndrome, Ehlers-Danlos Syndrome, familial aortic aneurysm, mitochondrial disease, cardiovascular sports medicine, exercise physiology and testing, adult congenital heart disease
American Society of Echocardiography
American Academy of Pediatrics
American College of Cardiology
American Heart Association
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 10/14/2015, Dr. Zahka has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.